Glenmark pharma launches generic version of Novartis' heart failure drug

Opens floodgates for more generic launches; 40 new brands expected

Sohini Das Mumbai
Photo: Reuters

Photo: Reuters

India’s Rs 20,000-crore cardiac drug market is in for a shake-up as generic launches of Novartis’ heart-failure drug Vymada begin. Mumbai-based Glenmark Pharmaceuticals on Monday announced the launch of their own brand of Sacubitril-valsartan tablets Sacu V, priced between Rs 19-35 per tablet.
Sheetal Sapale, president (marketing), AIOCD-AWACS said that at least 40 more brands are expected to be launched in this category, leading to a price erosion of at least 50 per cent.
Earlier in December, JB Pharma, which had acquired the Azmarda brand from Novartis AG, Switzerland for the India region for a consideration of Rs 246 crores in April 2022, had slashed its prices by half to Rs 39.6 per tablet. Only four companies were marketing Novartis’ drug in India who had acquired the brands from the innovator – Mankind, Dr Reddy’s Laboratories, JB Pharma apart from Novartis itself. Now, a slew of generic makers is set to ente

Also Read

Breather for Natco in Novartis cardiac drug case from Delhi High Court

Price war begins for Novartis cardiac drug as JB Pharma cuts rate by 50%

Bayer launches novel heart failure drug Verquvo for Rs 127 a pill

Sun Pharma's Q1 margins likely to be hit on elevated input costs: Analysts

Sun Pharma Q1 net profit soars 43% YoY to Rs 2,061 cr; revenue up 10%

Gera Developments buys land in Pune for themed residential project

PepsiCo plans to expand operation in Hyderabad, to add 1,200 workers

Network18 posts Rs 76.8 mn net loss in December quarter amid ad slowdown

Glenmark Pharmaceuticals launches drug to treat heart failure in India

Lenders select Ramkrishna Forgings resolution plan for ailing JMT Auto

First Published: Jan 17 2023 | 4:44 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on are available only to BS Premium subscribers. Already a BS Premium subscriber?LOGIN NOW

Register to